Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors

Key Points

• This research aims to evaluate the agreement between local and central HER2 IHC testing and assess the efficacy of trastuzumab deruxtecan based on HER2 IHC status.
• Conducted a post-hoc analysis of the DESTINY-PanTumor02 study
• Compared local and central HER2 IHC testing results
• Assessed the efficacy of trastuzumab deruxtecan by HER2 IHC status
• Moderate concordance between local and central IHC testing was observed
• The analysis suggests the need for a validated diagnostic test
• Findings indicate the importance of standardized algorithms for HER2 assessment